Live Breaking News & Updates on Therapeutics Media Contact

Stay updated with breaking news from Therapeutics media contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare's Precision Oncology Pipeline

/PRNewswire/ Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to. ....

United States , United Kingdom , New York , Lisa Burgner , Michaela Bowden , Brian Lamon , Head Of Biopharma Business Development , Therapeutics Inc , Verge Scientific Communications , Prnewswire Caris Life Sciences , Caris Life Sciences Media Contact , Caris Life Sciences Business Development Contact , Caris Life Sciences , Flare Therapeutics , Chief Development Officer , Milan Radovich , Senior Vice President , Chief Scientific Officer , Caris Life , Whole Exome , Whole Transcriptome Sequencing , Caris Assure , Life Sciences Media Contact , Life Sciences Business Development Contact , Business Officer , Biopharma Business ,

Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022

/PRNewswire/ Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will. ....

United Kingdom , Liz Philips , Erica Fiorini , Vertex Pharmaceuticals , Prnewswire Obsidian Therapeutics Inc , Bristol Myers Squibb , Russo Partners , Obsidian Therapeutics Inc , Itinerary Planner , Chief Scientific Officer , Presentation Date , Cellular Therapies , Therapeutics Media Contact , Obsidian Therapeutics ,

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to

– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXE. ....

New Haven , United States , Yale University , Stephen Basso , Hal Mackins , Michael Morrissey , Varant Shirvanian , Daiichi Sankyo Company , Technology Platform , Genentech Inc , Exchange Commission , Hlip Inc , Exelixis Inc , University Of Rhode Island , Cybrexa Therapeutics , H Low Insertion Peptide , Per Hellsund , H Low Insertion Peptides , Rhode Island , Advantage Capital Connecticut , Connecticut Innovations , Elm Street Ventures , Exelixi Quarterly Report , Investors Contact , Investor Relations , Media Contact ,

Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12

Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New Haven , United States , Yale University , Stephen Basso , Hal Mackins , Tara Dimilia , Michael Morrissey , Varant Shirvanian , Daiichi Sankyo Company , Technology Platform , Genentech Inc , Exchange Commission , Hlip Inc , Exelixis Inc , University Of Rhode Island , Cybrexa Therapeutics , H Low Insertion Peptide , Per Hellsund , H Low Insertion Peptides , Rhode Island , Advantage Capital Connecticut , Connecticut Innovations , Elm Street Ventures , Exelixi Quarterly Report , Investors Contact , Media Contact ,

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Erica Fiorini , Bristol Myers Squibb , Paulk Wotton , Vertex Pharmaceuticals , Prnewswire Obsidian Therapeutics Inc , Liz Philipsrusso Partners , Obsidian Therapeutics Inc , Chief Executive Officer , Therapeutics Media Contact ,